Page 8 - Pharmaceutical Firms

India may overhaul clinical trial ecosystem for faster drug availability

At a meeting last month, government officials discussed the proposal to set up clinical trial centres at institutions affiliated with the ICMR, replacing the current system

Eris Lifesciences soars 7%, hits five-month high in a weak market

In October, some large domestic mutual funds took an aggressive position in the stock, monthly disclosures show

Piramal Pharma partners with Norway firm to develop leukemia treatment drug

Piramal Pharma Solutions will partner, Bemcentinib, an AXL protein inhibitor for oncology which was recently designated as a Fast Track drug by the US Food and Drug Administration

Strong domestic and export growth to drive Ipca Laboratories' earnings

Ipca's first half performance holds testimony to its robust growth with India business growing in mid-teens

Textiles to pharma: India's deepening slowdown explained in six charts

What could be the reason for these successive downward revisions across the board? Some key indicators make it evident.

Aurobindo Pharma receives 8 US FDA observations for two of its facilities

Observations are related to procedural improvements, not data integrity, says the company

Medicines costing less than Rs 5 per dose may be taken out of price control

If this goes through, drugmakers will have the liberty to raise the prices of these drugs by up to 10 per cent every year

GSK gains 38% over 3 months, gets boost from tighter low-end portfolio

Revenue growth, margins have been trending up over the past couple of quarters

Glenmark Pharmaceuticals shareholders may get higher dividend in FY21

Monetisation of API, innovative business units planned this year

Drug regulator making list of dual-use APIs imported from unregistered cos

The CDSCO is strictly monitoring the import of such dual-use APIs for the last few months so as to get an idea on what kind of action should be taken

Biocon looks to derive sales from US, EU to break even at Malaysia unit

According to an Edelweiss report, investments would pick up at the company subsidiary in the current financial year

From auto to banking, grumble of slowdown is getting louder for India Inc

The companies' combined net profit declined by 10.1 per cent yoy during June '19 quarter against 26.2 per cent yoy growth a year ago

Wockhardt consolidated net loss narrows to Rs 45 cr for June 2019 quarter

Total income of the company stood at Rs 871.19 crore during the quarter under review

As price pressure mounts, pharma companies tap analytics to cut costs

Cipla is the first company in the Asia Pacific to upgrade to a cloud-based pharmacovigilance solution

India's new drug nods from US dip in Q1 due to increased scrutiny on firms

India's share of ANDA approvals given by the US Food and Drug Administration (USFDA), too, has fallen from 43 per cent in fourth quarter (Q4) of 2018-19 (FY19) to 33 per cent in Q1FY20

Growth in US business likely to boost Q1 revenues of pharma companies

According to Edelweiss Securities, pharma sales to grow by 17 per cent YoY as US sales are expected to grow by 21 per cent YoY

It's time for India's one-brand pharma firms to scale up, diversify

Many of these brands are not protected against the discovery a new, more efficient molecule as the small firms that own them have not kept pace with the latest research